453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

T. Doi, M. Patel,G.S. Falchook, T. Koyama,C.F. Friedman,S. Piha-Paul,M.E. Gutierrez, R. Abdul-Karim, M. Awad,D.R. Adkins,S. Takahashi, S. Kadowaki, B. Cheng, N. Ikeda, A. Laadem,N. Yoshizuka,M. Qian,O. Dosunmu,H-T. Arkenau,M.L. Johnson

ANNALS OF ONCOLOGY（2022）

Cited 7|Views0

No score

Abstract

B7-H3 overexpression correlates with poor prognosis in many cancers. DS-7300 is a B7-H3–directed ADC with a topoisomerase I inhibitor payload (DXd). The DS-7300 dose finding study (NCT04145622) showed that DS-7300 was generally well tolerated with early signs of antitumor activity. We present extended follow-up data for a larger cohort of participants (pt) with selected tumor types.

Translated text

Key words

durable antitumor activity,advanced solid tumors,antibody-drug

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined